Effectiveness and Safety of Bempedoic Acid in Taiwanese Patients With Hypercholesterolemia: A Pragmatic Phase 4 Study (CLEAR Taiwan Study)

Journal of the American Heart Association 2026 Open access

Read full text
Authors: I-Chang Hsieh, Dong‐Yi Chen, Chih-Sheng Chu, Yi‐Yao Chang, Bing-Hsiean Tzeng, Tien-Chi Huang, Heng‐Hsu Lin, Wen‐Po Chuang, Chun‐Yao Huang, Jih‐Kai Yeh, Chun‐Yuan Chu, Ming-Yun Ho
+5 more Chun‐Yao Huang, Yu-Wen Chen, Wei-Chen Yang, T-M Lin, Yen‐Wen Wu
DOI: 10.1161/jaha.126.049917
Cited by: 1
References: 30

Abstract

BACKGROUND: Elevated low-density lipoprotein cholesterol (LDL-C) is a risk factor for cardiovascular disease. Despite available lipid-lowering therapies, lipid control remains suboptimal. Bempedoic acid offers a nonstatin oral treatment for hypercholesterolemia. However, real-world data in Asia are limited. The study aimed to investigate the effectiveness and safety of bempedoic acid in Taiwan. METHODS: This prospective, pragmatic phase 4 study enrolled 180 patients with inadequately controlled hypercholesterolemia to receive bempedoic acid for 12 weeks in addition to background lipid-lowering therapy. The primary end point was the percentage change in LDL-C. Secondary end points included changes in other lipid parameters, hs-CRP (high-sensitivity C-reactive protein), and safety outcomes. RESULTS: >0.05). At week 12, 31.3% of patients achieved LDL-C targets (

Fields of Study & Subjects

Lipoproteins and Cardiovascular Health Diabetes Cardiovascular Risks and Lipoproteins Diabetes Treatment and Management

Publication details

Journal / source
Journal of the American Heart Association
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
15
Issue
10
Pages
e049917–e049917
Publication date
15 May 2026
Language
EN